Article
Rheumatoid arthritis (RA) has long been established to have pulmonary manifestations such as interstitial lung disease (ILD), and several research groups are pursuing this respiratory burden of RA at #ACR20.
All News
Article
Febuxostat, a nonpurine xanthine oxidase inhibitor used in the treatment of chronic gout to lower serum urate levels, received bad press in 2019 after the US Food and Drug Administration (FDA) placed a black-box warning on the medication’s label suggesting that it increases the risk of cardiovasc
Dr. John Cush
Tweet
#BestACR20Tweets
RT @drdavidliew :The 'triple M' irAEs (myositis/myocarditis/MG): one of the rheumatic irAEs where autoAb are freq pos
Nice systematic review:
any autoAb+ 61% tested
MG+ 59% tested
MSA+ in 27% tested (18/67, 11 had myositis alone) https://t.co/aQHapPbjw9
Dr. John Cush
Tweet
#BestACR20Tweets
RT @MeralElRamahiMD : A large observat study showed no difference in risk of major CV events in RA pts that were newly started on either MTX or HCQ. A greater stroke risk but lower risk of MI; hospitalized HF was seen in MTX initiators. #Abst1993 #ACR20
Dr. John Cush
Tweet
The Lungs: The Alpha and Omega of RA with Dr. Jonathan Kay #ACR20
https://t.co/zhCRaeKOfu https://t.co/zVwgzu9ULs
Dr. John Cush
Tweet
Citrulline Reactive B Cells Present in Lungs of Risk, Early RA: Richard Conway ( @RichardPAConway) discusses ACR abstract #1445 presented #ACR20
https://t.co/WjcBPay86P https://t.co/JnUVss0FDK
Dr. John Cush
Tweet
#BestACR20Tweets
RT @KDAO2011 : The FAST trial had 33% of pts with CVD and pts w/class III/IV CHF weren't allowed in this study; still cautious prescribing febuxostat to pts who have severe CVD until we have more data. https://t.co/eyl2kOjEEU https://t.co/qoQDgRifFg
Dr. John Cush
Tweet
Check out this quick video on lifestyle, clinical risk factors for RA-ILD with Dr. Sheila Reyes (@RHEUMarampa) #ACR20
https://t.co/7LQ7RCtiuj https://t.co/CjjtUauy2u
Dr. John Cush
Tweet
"Rheumatoid arthritis and lung disease in the spotlight at #ACR20" by Dr. Jeffrey Sparks ( @jeffsparks)
https://t.co/0Dth0ko5TO https://t.co/e6HQOkXuY7
Dr. John Cush
Tweet
View our video on Abatacept in RA and ILD Patients with Dr Richard Conway ( @RichardPAConway)
Dr. Richard Conway discusses abstract #0233 presented Friday at the #ACR20 virtual annual meeting.
https://t.co/5zowsDetU1
Sebastian E. Sattui MD, MS
Tweet
#ACR20 Abstracts on #ILD
Rituximab in ILD (all observational)
#1053 ➡️ 47 with CTD-ILD: overall improvement or stability at 36m
#1051 ➡️ 50 with IPAF: >70% stable or improved at 12m
#1047 ➡️ 47 patients CTD-ILD or IPAF: good experience with MMF and RTX
#ACRambassador https://t.co/klfVwIH5b6
The Lancet
Tweet
Latebreaking at #ACR20—Febuxostat was non-inferior to allopurinol with regard to the occurrence of major cardiovascular outcomes in patients with gout: finding from FAST, multicentre, prospective, randomised, open-label, non-inferiority trial https://t.co/cpoNi7zjwi https://t.co/uQyeyepPmj
k dao
Tweet
The FAST trial had 33% of pts with CVD and pts w/class III/IV CHF were not allowed in this study (vs. CARES trial where all subjects had baseline CVD); I am still cautious prescribing febuxostat to pts who have severe CVD until we have more data. @RheumNow https://t.co/fJ9bLcXpR2
Dr. John Cush
Tweet
IN GOUT: CARES study said febuxostat increases CV risk; Todays FAST study says No incr CV risk w/ FEB. In your Gout pt w/ CV hx, would you use febuxostat? #ACR2020
Dr. John Cush
Tweet
FAST trial (Plenary) showed opposite of CAREs study. Febuxostat vs PBO in 6128 Gout pts, showed little dropout (~6%) in a 4 year study. Febuxostat (mean 81mg) had similar, flare rates, MACE/cardiac endpoints and CV death vs allopurinol #ACR20 Abstr#L08 https://t.co/FkdDtPB4Oi https://t.co/J9KonQHpT2
Meral K. El Ramahi, MD
Tweet
A large observat study showed no difference in risk of major CV events in RA pts that were newly started on either MTX or HCQ. A greater stroke risk but lower risk of MI & hospitalized HF was seen in MTX initiators. #Abst1993 #ACR20 @RheumNow
Dr. John Cush
Tweet
Abatacept in RA and ILD Patients: Dr Richard Conway (@RichardPAConway) #ACR20
https://t.co/e31VsnXFq5 https://t.co/sCrqLtXFFc
Meral K. El Ramahi, MD
Tweet
#ACRbest Largest to date cohort study of pregnancies in women w/ ILD showed no maternal deaths suggesting that women w/ ILD may not need to avoid conception or terminate pregnancies, but pts w/ severe ILD were at higher risk for poor pregnancy outcomes. #Abst1446 @RheumNow
Meral K. El Ramahi, MD
Tweet
Poll results are in! 75% of those that responded plan to only screen for cardiac manifestations of myositis if a pt develops concerning symptoms. 20% screen for involvement annually w/ a TTE, troponin, BNP, and EKG! @RheumNow #ACR20 https://t.co/crUhFR6Hzf
Olga Petryna
Tweet
@RheumNow #ACR20 abs1151 screening for inflammatory hyperferritinemia may be feasible but requires additional info: inflammatory huperferritinemia more likely to correlate with ⬆️IL18, AST&thrombocytosis while high CRP+ferritin more often seen in infectious etiology https://t.co/wiFPXepxpz
